Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels
Sibille, A., Henket, M., Corhay, J. L., Louis, R., Duysinx, B.Language:
english
Journal:
Acta Oncologica
DOI:
10.1080/0284186x.2019.1695063
Date:
November, 2019
File:
PDF, 619 KB
english, 2019